Leviathan Metals has begun a combined Reverse Circulation and percussion drilling program of up to 2,500 meters at its Serule and Foley uranium projects in Botswana. The drilling aims to explore extensions of westward-dipping uranium mineralization seen at the adjacent Letlhakane property, which hosts significant indicated and inferred uranium resources. Previous 2024 drilling at Serule showed promising uranium grades between 196 and 1,247 ppm U3O8. The company highlights good infrastructure access and plans to continue exploration alongside its ongoing Kalahari Copper Belt project. Results from this program will help assess the potential for further uranium resources in the region.
Leviathan Metals' uranium drilling program in Botswana provides context for Basic Materials sector activity on Pluang. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 19, 2026 18:11 WIB: out of 83 priced US stocks, 44 rose and 29 fell. Notable movers include LAC at USD 2.24 (+2.75%), CRS at USD 386.12 (+2.39%), and USAR at USD 10.78 (+2.28%). Typical hold times vary from 2 to 28 days.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
